|
시장보고서
상품코드
2078576
파킨슨병(PD) 치료제 시장(2026-2030년)Global Parkinsons Disease (PD) Drugs Market 2026-2030 |
||||||
세계의 파킨슨병(PD) 치료제 시장은 2025-2030년 17억 8,390만 달러 증가하고, 예측 기간 중 연평균 복합 성장률(CAGR)은 5.5%를 기록할 것으로 예측됩니다.
본 보고서에서는 전 세계 파킨슨병(PD) 치료제 시장에 대해 종합적인 분석, 시장 규모 및 전망, 동향, 성장 요인, 과제는 물론 약 25개 업체에 대한 분석을 제공합니다.
본 보고서에서는 현재 시장 상황, 최신 동향 및 성장요인, 그리고 시장 환경 전반에 대한 최신 분석을 제공합니다. 이 시장의 성장은 전 세계 고령 인구의 급증과 이에 따른 질환 유병률 상승, 질환 수정 요법에 대한 투자 확대 및 파이프라인의 고도화된 다각화, 디지털 바이오마커와 첨단 진단 기술의 통합이 진행되고 있는 점 등에 의해 주도되고 있습니다.
본 조사는 업계 주요 관계자들의 의견을 포함한 1차 정보와 2차 정보를 객관적으로 종합하여 실시되었습니다. 본 보고서에는 주요 기업에 대한 분석 외에도 종합적인 시장 규모 데이터, 지역별 분석을 포함한 부문별 데이터, 그리고 공급업체 현황이 수록되어 있습니다. 또한, 과거 데이터와 예측 데이터도 포함되어 있습니다.
| 시장 범위 | |
|---|---|
| 기준연도 | 2025년 |
| 종료연도 | 2030년 |
| 조사 기간 | 2026-2030년 |
| 성장 모멘텀 | 가속 |
| YOY 2026 | 5.3% |
| CAGR | 5.5% |
| 증가액 | 17억 8,390만 달러 |
본 조사에서는 향후 몇 년간 전 세계 파킨슨병(PD) 치료제 시장의 성장을 견인할 주요 요인 중 하나로, 유전자 모니터링 및 바이오마커를 활용한 표적 치료 하위 부문으로의 전환이 꼽히고 있습니다. 또한, 지속형 약물 전달 시스템과 첨단 기기 및 약제의 조합 도입이 확대되고, 재생의료(세포 치료) 및 유전자 변형 치료가 업계에 점차 확산됨에 따라 시장에서 상당한 수요가 발생할 것으로 전망됩니다.
목차
제1장 주요 요약
제2장 Technavio 분석
제3장 시장 구도
제4장 시장 규모
제5장 시장 규모 실적
제6장 정성 분석
제7장 Five Forces 분석
제8장 시장 세분화 : 약제 클래스별
제9장 시장 세분화 : 유통 채널별
제10장 시장 세분화 : 투여 경로별
제11장 고객 현황
제12장 지역별 상황
제13장 성장 촉진요인, 과제 및 기회
제14장 경쟁 구도
제15장 경쟁 분석
제16장 부록
LSHThe global parkinsons disease (PD) drugs market is forecasted to grow by USD 1783.9 mn during 2025-2030, accelerating at a CAGR of 5.5% during the forecast period. The report on the global parkinsons disease (PD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by exponential expansion of global geriatric demographic and associated disease prevalence, accelerated investment in disease-modifying therapeutics and advanced pipeline diversification, increasing integration of digital biomarkers and advanced diagnostic technologies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 5.3% |
| CAGR | 5.5% |
| Incremental Value | $1783.9 mn |
Technavio's global parkinsons disease (PD) drugs market is segmented as below:
By Drug Class
- Carbidopa-levodopa
- Anticholinergics
- Dopamine agonists
- MAO-B inhibitors
- Others
By Distribution Channel
- Retail pharmacy
- Hospital pharmacy
- Online pharmacy
By Route Of Administration
- Oral
- Infusion
- Transdermal
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the shift toward targeted genetically monitored and biomarker-driven treatment sub-segments as one of the prime reasons driving the global parkinsons disease (PD) drugs market growth during the next few years. Also, increasing adoption of continuous drug delivery systems and advanced device-drug combinations and rising industry penetration of regenerative cell-based therapies and gene modification modalities will lead to sizable demand in the market.
The report on the global parkinsons disease (PD) drugs market covers the following areas:
- Global parkinsons disease (PD) drugs market sizing
- Global parkinsons disease (PD) drugs market forecast
- Global parkinsons disease (PD) drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global parkinsons disease (PD) drugs market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Health Co Inc., Bristol Myers Squibb Co., H. Lundbeck AS, Ipsen Pharma, Kyowa Kirin Co. Ltd., Merz Pharma GmbH and Co. KGaA, Mitsubishi Tanabe Pharma Corp., Neurocrine Biosciences Inc., Novartis AG, Orion Corp., Pfizer Inc., Sun Pharmaceutical Industries, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Ltd., UCB SA, Voyager Therapeutics Inc, ZAMBON CO S.P.A.. Also, the global parkinsons disease (PD) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Parkinsons Disease (PD) Drugs Market 2020 - 2024
- Historic Market Size - Data Table on Global Parkinsons Disease (PD) Drugs Market 2020 - 2024 ($ million)
- 5.2 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
- 5.3 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
- 5.4 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global parkinsons disease (PD) drugs market
- 6.2 Impact of geopolitical conflicts on global parkinsons disease (PD) drugs market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Drug Class
- 8.1 Market segments
- 8.2 Comparison by Drug Class
- 8.3 Carbidopa-levodopa - Market size and forecast 2025-2030
- 8.4 Anticholinergics - Market size and forecast 2025-2030
- 8.5 Dopamine agonists - Market size and forecast 2025-2030
- 8.6 MAO-B inhibitors - Market size and forecast 2025-2030
- 8.7 Others - Market size and forecast 2025-2030
- 8.8 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
9 Market Segmentation by Distribution Channel
- 9.1 Market segments
- 9.2 Comparison by Distribution Channel
- 9.3 Retail pharmacy - Market size and forecast 2025-2030
- 9.4 Hospital pharmacy - Market size and forecast 2025-2030
- 9.5 Online pharmacy - Market size and forecast 2025-2030
- 9.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
10 Market Segmentation by Route of Administration
- 10.1 Market segments
- 10.2 Comparison by Route of Administration
- 10.3 Oral - Market size and forecast 2025-2030
- 10.4 Infusion - Market size and forecast 2025-2030
- 10.5 Transdermal - Market size and forecast 2025-2030
- 10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 Japan - Market size and forecast 2025-2030
- 12.5.2 China - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Thailand - Market size and forecast 2025-2030
- 12.5.6 Taiwan - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Australia - Market size and forecast 2025-2030
- 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.4 South Africa - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 UAE - Market size and forecast 2025-2030
- 12.6.7 Turkey - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Exponential expansion of global geriatric demographic and associated disease prevalence
- Accelerated investment in disease-modifying therapeutics and advanced pipeline diversification
- Increasing integration of digital biomarkers and advanced diagnostic technologies
- 13.2 Market challenges
- High rates of attrition and clinical trial failures for neuroprotective compounds
- Stringent and inconsistent regulatory standards across major global regions
- Complex industry access, pricing disparities, and reimbursement hurdles in global economies
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Shift toward targeted genetically monitored and biomarker-driven treatment sub-segments
- Increasing adoption of continuous drug delivery systems and advanced device-drug combinations
- Rising industry penetration of regenerative cell-based therapies and gene modification modalities
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 15.6 Bausch Health Co Inc.
- Bausch Health Co Inc. - Overview
- Bausch Health Co Inc. - Business segments
- Bausch Health Co Inc. - Key offerings
- Bausch Health Co Inc. - Segment focus
- SWOT
- 15.7 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.8 Ipsen Pharma
- Ipsen Pharma - Overview
- Ipsen Pharma - Business segments
- Ipsen Pharma - Key offerings
- Ipsen Pharma - Segment focus
- SWOT
- 15.9 Kyowa Kirin Co. Ltd.
- Kyowa Kirin Co. Ltd. - Overview
- Kyowa Kirin Co. Ltd. - Business segments
- Kyowa Kirin Co. Ltd. - Key offerings
- Kyowa Kirin Co. Ltd. - Segment focus
- SWOT
- 15.10 Mitsubishi Tanabe Pharma Corp.
- Mitsubishi Tanabe Pharma Corp. - Overview
- Mitsubishi Tanabe Pharma Corp. - Product / Service
- Mitsubishi Tanabe Pharma Corp. - Key offerings
- SWOT
- 15.11 Neurocrine Biosciences Inc.
- Neurocrine Biosciences Inc. - Overview
- Neurocrine Biosciences Inc. - Product / Service
- Neurocrine Biosciences Inc. - Key offerings
- SWOT
- 15.12 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.13 Orion Corp.
- Orion Corp. - Overview
- Orion Corp. - Product / Service
- Orion Corp. - Key offerings
- SWOT
- 15.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.15 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Business segments
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- Sun Pharmaceutical Industries - Segment focus
- SWOT
- 15.16 Supernus Pharmaceuticals Inc.
- Supernus Pharmaceuticals Inc. - Overview
- Supernus Pharmaceuticals Inc. - Product / Service
- Supernus Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.17 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 UCB SA
- UCB SA - Overview
- UCB SA - Product / Service
- UCB SA - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
